Gary Nachman (Raymond James)

Focus Areas4 topics

Competitive Dynamics3Revenue Growth1Demand1Pricing1

Trends3 quarters

Questions per Quarter

Questions

Challenging

Companies Covered

Question History3 questions

ABBVAbbVie1 quarter

2025 Q2

What are you seeing regarding the competitive dynamics in the IL-23 class, especially with J&J's TREMFYA with their new IBD approvals

Competitive DynamicsRevenue GrowthView in transcript →

ALNYAlnylam Pharmaceuticals2 quarters

2025 Q1

is that creating a headwind for AMVUTTRA's launch in CM or is it helping create more noise for the entire category

Competitive DynamicsDemandView in transcript →

2024 Q4

talk about the competitive dynamics you're seeing with Wainua in polyneuropathy with both products growing

Competitive DynamicsPricingView in transcript →